HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.8%

Neg 0% Neu 89.8% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $310 price target.